The DOI matches its Crossref record; 187 of the 188 references it cites were found in a registry or an index.
Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics
Open accessAbstract
Therapeutic gene silencing promises significant progress in pharmacotherapy, including considerable expansion of the druggable target space and the possibility for treating orphan diseases. Technological hurdles have complicated the efficient use of therapeutic oligonucleotides, and siRNA agents suffer particularly from insufficient pharmacokinetic properties and poor cellular uptake. Intense development and evolution of delivery systems have resulted in efficient uptake predominantly in liver tissue, in which practically all nanoparticulate and liposomal delivery systems show the highest accumulation. The most efficacious strategies include liposomes and bioconjugations with N-acetylgalactosamine. Both are in early clinical evaluation stages for treatment of liver-associated diseases. Approaches for achieving knockdown in other tissues and tumors have been proven to be more complicated. Selective targeting to tumors may be enabled through careful modulation of physical properties, such as particle size, or by taking advantage of specific targeting ligands. Significant barriers stand between sufficient accumulation in other organs, including endothelial barriers, cellular membranes, and the endosome. The brain, which is shielded by the blood-brain barrier, is of particular interest to facilitate efficient oligonucleotide therapy of neurological diseases. Transcytosis of the blood-brain barrier through receptor-specific docking is investigated to increase accumulation in the central nervous system. In this review, the current clinical status of siRNA therapeutics is summarized, as well as innovative and promising preclinical concepts employing tissue- and tumor-targeted ligands. The requirements and the respective advantages and drawbacks of bioconjugates and ligand-decorated lipid or polymeric particles are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Strategies that have been applied for achieving functional siRNA delivery into the brain mainly rely on employing potent protein or peptide ligands to target the receptors, such as transferrin, insulin and LDL receptors, which are highly expressed on the blood brain barrier (BBB).[102]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [102]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429 · cited 1×
“This is not surprising, considering the fact that RNA interference was only discovered in 1998 [27], and it took nearly a decade to fully elucidate its mechanism and determine guidelines for sequence design, length, chemical modifications, and formulations [28].”
BackgroundValadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930 · cited 3×
“75NTR are possible targets − Peptide/siRNA complexes [113] − Polyethyleneimine complexes [115] − Liposomes [116] − PAMAM nanoparticles [117] − Targeted exosomes [114] − Protamine-antibody/siRNA complexes [126] − Liposomes [127] − Polythyleneimine complexes [135–137] − PEG–siRNA conjugate [138] − Self-assembled nanopar…”
BackgroundMethodHow many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115 · cited 1×
“The main issues yet to be resolved are substrate stability, cellular uptake and endosomal escape, and pharmacokinetics [30,31].”
BackgroundDoherty, G. J., & McMahon, H. T. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081307.110540 · Cited by 3,075 · cited 1×
“There are several pathways of endocytosis, the clathrin-coated pit pathway, the caveolar-dependent uptake, clathrin- and caveolinindependent pathways, and macropinocytosis [90–93].”
BackgroundBiomolecular coronas provide the biological identity of nanosized materials
Monopoli, M. P., Åberg, C., Salvati, A., & Dawson, K. A. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.207 · Cited by 3,017
Huotari, J., & Helenius, A. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.286 · Cited by 2,448
Keefe, A. D., Pai, S., & Ellington, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3141 · Cited by 2,289 · cited 1×
“Depending on their mechanism of action, therapeutic oligonucleotides are categorized into several classes: Antisense [6,7], aptamers [8], splice correcting oligonucleotide [9,10], siRNA [1], miRNA mimics and antagonists [11], immunomodulating agents [12] and decoys [13] are themost important ones.”
BackgroundTreatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E., Zeuzem, S., Rodriguez‐Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A. P., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,262
Flagged first, then by citations
1 of the 188 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Emerging Frontiers in Drug Delivery
Tibbitt, M. W., Dahlman, J. E., & Langer, R. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b09974 · Cited by 1,009
The delivery of therapeutic oligonucleotides
Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 882
“This approach has been especially important for therapeutic use of siRNA (164) and good accounts of current clinical trials using siRNA LNPs are found in recent reviews (10,165).”
BackgroundAntisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H. T. T., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 586
Kim, S. M., Yang, Y., Oh, S. J., Hong, Y., Seo, M., & Jang, M. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.013 · Cited by 481
Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives
Poller, W. C., Dimmeler, S., Heymans, S. R. B., Zeller, T., Haas, J., Karakas, M., Leistner, D. M., Jakob, P., Nakagawa, S., Blankenberg, S., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx165 · Cited by 417
Metadata
- Authors
- Lorenzer, C., Dirin, M., Winkler, A.-M., Baumann, V., & Winkler, J.
- Affiliations
- University of Vienna (AT)
- Corresponding author
- Winkler, Johannes
- ORCID
- Winkler, Johannes
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 203
- Pages
- 1-15
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2019613864
- Cited by
- 284
- References
- 188
- Citations by year
- 2026: 7 · 2025: 16 · 2024: 17 · 2023: 17 · 2022: 22 · 2021: 25 · 2020: 23 · 2019: 35 · 2018: 34 · 2017: 33 · 2016: 37 · 2015: 18
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Controlled Release (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- FWF (I519-B11)
- Innovative Medicines Initiative Joint Undertaking (115363)
- European Union's (FP7/2007–2013)
- EFPIA companies'
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- siRNA therapeutics, targeted delivery, gene silencing, liposomes, nanoparticle drug delivery, tumor targeting, blood-brain barrier, transcytosis, cellular uptake, pharmacokinetics, oligonucleotide therapeutics, liver-targeted drug delivery
- MeSH terms
- RNAi Therapeutics, Animals, Blood-Brain Barrier, Endothelium, Humans, Leukocytes, Liposomes, Liver, Models, Molecular, Neoplasms, Drug Delivery Systems, Gene Transfer Techniques, RNA, Small Interfering, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
